{"id":131835,"date":"2022-08-01T05:27:54","date_gmt":"2022-08-01T09:27:54","guid":{"rendered":"https:\/\/44.250.171.167\/?p=131835"},"modified":"2022-10-06T04:55:35","modified_gmt":"2022-10-06T08:55:35","slug":"sun-pharmaceutical-industries-ltd-q1-fy23-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/sun-pharmaceutical-industries-ltd-q1-fy23-earnings-conference-call-insights\/","title":{"rendered":"Sun Pharmaceutical Industries Ltd Q1 FY23 Earnings Conference Call Insights"},"content":{"rendered":"<p><strong>Key highlights from Sun Pharmaceutical Industries Ltd (<a href=\"https:\/\/44.250.171.167\/symbol\/SUNPHARMA\/\">SUNPHARMA<\/a>) Q1 FY23 Earnings Concall<\/strong><\/p>\n<p><strong>Management Update:<\/strong><\/p>\n<ul>\n<li>SUNPHARMA recorded the highest ever quarterly revenue in 1Q23, with sales increasing 14% YonY, excluding the contribution of 1Q22.<\/li>\n<\/ul>\n<ul>\n<li>SUNPHARMA\u2019s current generic pipeline for the US includes 89 ANDAs and 13 NDAs awaiting approval with the US FDA.<\/li>\n<\/ul>\n<p><strong>Q&amp;A Highlights:<\/strong><\/p>\n<ul>\n<li>Kunal Dhamesha of Macquarie Capital asked that on Taro, if there is any one-off related to integration cost in the SG&amp;A expense. Dilip Shanghvi MD replied the company cannot give any more information further to what Taro has given.<\/li>\n<\/ul>\n<ul>\n<li>Kunal Dhamesha of Macquarie Capital also asked about psoriatic arthritis trial, if the revised timelines have been fixed. Dilip Shanghvi MD replied that the company has not given guidelines of the completion of the trial. However, the challenges in both Ukrain and Russia have contributed to potential delay.<\/li>\n<\/ul>\n<ul>\n<li>Prakash Agarwal from Axis Capital enquired about the drivers of double digit growth in staff, SG&amp;A and R&amp;D YoY and QonQ. C. S. Muralidharan CFO replied that the expenses will be increasing as the operations normalize. Also there is no specific forex -related component included in that.<\/li>\n<\/ul>\n<ul>\n<li>Prakash Agarwal from Axis Capital asked about CEQUA that post entry of generic for RESTASIS, if there is any change in market dynamics for pricing or prescription pickup for branded products. C. S. Muralidharan CFO said it\u2019s not seeing any change. But looking at the market share, post launch of generic, SUNPHARMA has been able to show an increase in market share.<\/li>\n<\/ul>\n<ul>\n<li>Damayanti Kerai with HSBC asked that on the Halol plant and any timeline update from FDA. Dilip Shanghvi MD replied that the company is awaiting the Establishment Inspection Report (EIR), post which the company can say, else SUNPHARMA continue to update FDA about the remediation for all the 483s received.<\/li>\n<\/ul>\n<ul>\n<li>Neha Manpuria of Bank of America asked about Winlevi, the reason for it stabilizing after the initial momentum. Abhay Gandhi CEO, North America replied that it is because of the summer months where the derm products generally slow down a bit for the last 8-9 weeks. But QonQ it is up 22%.<\/li>\n<\/ul>\n<ul>\n<li>Neha Manpuria of Bank of America asked that in terms of contribution of Winlevi, when does the company see adequate formulary recovery to start seeing Winlevi contribution. Abhay Gandhi CEO, North America replied the company is positive about Winlevi and will keep investing in the product.<\/li>\n<\/ul>\n<ul>\n<li>Krish Mehta from Enam Holdings enquired about the other income being low in 1Q23 and the outlook going forward. C. S. Muralidharan CFO said other income is not very core to the overall business. It includes various moving parts which fluctuates from QtoQ and there is no one-offs.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from Sun Pharmaceutical Industries Ltd (SUNPHARMA) Q1 FY23 Earnings Concall Management Update: SUNPHARMA recorded the highest ever quarterly revenue in 1Q23, with sales increasing 14% YonY, excluding the contribution of 1Q22. SUNPHARMA\u2019s current generic pipeline for the US includes 89 ANDAs and 13 NDAs awaiting approval with the US FDA. Q&amp;A Highlights: Kunal [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"Sun Pharmaceutical Industries Ltd Q1 FY23 Earnings Conference Call Insights #SUNPHARMA #Q1 #FY23","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5747],"tags":[8157,1115],"class_list":["post-131835","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-healthcare-stocks","tag-healthcare","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":135427,"url":"https:\/\/alphastreet.com\/india\/sun-pharmaceutical-industries-limited-q2-fy23-earnings-conference-call-insights\/","url_meta":{"origin":131835,"position":0},"title":"Sun Pharmaceutical Industries Limited Q2 FY23 Earnings Conference Call Insights","author":"Praveen","date":"November 3, 2022","format":false,"excerpt":"Key highlights from Sun Pharmaceutical Industries Limited (SUNPHARMA) Q2 FY23 Earnings Concall Q&A Highlights: [00:16:46] Tushar Manudhane of Motilal Oswal asked about the sustainability of US generics business and its sales tracking well despite ANDA approval and filing reducing. Abhay Gandhi CEO replied that the pace of approval is not\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":166804,"url":"https:\/\/alphastreet.com\/india\/sunpharma-q3-2024-2025-call-highlights-india-leads-us-slows-specialty-expands\/","url_meta":{"origin":131835,"position":1},"title":"SUNPHARMA Q3 2024-2025 Call Highlights: India Leads, US Slows, Specialty Expands!","author":"Praveen","date":"February 11, 2025","format":false,"excerpt":"Sun Pharmaceutical Industries Ltd., the fourth largest specialty generic pharmaceutical company in the world, in its Q3 earnings call discussed about strong Q3 performance with significant specialty business growth, though the company expects lower specialty sales next quarter due to inventory buildup at partner locations. The company's India business grew\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/CC_Image_8.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/CC_Image_8.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/CC_Image_8.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/CC_Image_8.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":132898,"url":"https:\/\/alphastreet.com\/india\/sun-pharmaceutical-industries-ltd-sunpharma-q1-fy23-earnings-concall-transcript\/","url_meta":{"origin":131835,"position":2},"title":"Sun Pharmaceutical Industries Ltd (SUNPHARMA) Q1 FY23 Earnings Concall Transcript","author":"IRS_INDIA","date":"July 29, 2022","format":false,"excerpt":"Sun Pharmaceutical Industries Ltd (NSE:SUNPHARMA) Q1 FY23 Earnings Concall dated Jul. 29, 2022 Corporate Participants: Nimish Desai -- Investor Relations Dilip Shanghvi -- Managing Director C. S. Muralidharan -- Chief Financial Officer Kirti Ganorkar -- Chief Executive Officer, India Business Abhay Gandhi -- Chief Executive Officer, North America Analysts: Kunal\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"Earnings Conference Call Transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":139815,"url":"https:\/\/alphastreet.com\/india\/sun-pharmaceutical-industries-limited-sunpharma-q3-fy23-earnings-concall-transcript\/","url_meta":{"origin":131835,"position":3},"title":"Sun Pharmaceutical Industries Limited (SUNPHARMA) Q3 FY23 Earnings Concall Transcript","author":"IRS_INDIA","date":"January 31, 2023","format":false,"excerpt":"Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA) Q3 FY23 Earnings Concall dated Jan. 31, 2023 Corporate Participants: Abhishek Sharma\u00a0--\u00a0Head of Investor Relations and Strategic Projects Dilip Shanghvi\u00a0--\u00a0Managing Director C. S. Muralidharan\u00a0--\u00a0Group Chief Financial Officer Kirti Ganorkar\u00a0--\u00a0Chief Executive Officer-India Business Abhay Gandhi\u00a0--\u00a0Chief Executive Officer-North America Business Analysts: Naushad Chaudhary\u00a0--\u00a0Aditya Birla Sun Life\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"Earnings Conference Call Transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":147686,"url":"https:\/\/alphastreet.com\/india\/sun-pharmaceutical-indus-sunpharma-q4-fy23-earnings-concall-transcript\/","url_meta":{"origin":131835,"position":4},"title":"SUN PHARMACEUTICAL INDUSTRIES LIMITED (SUNPHARMA) Q4 FY23 Earnings Concall Transcript","author":"IRS_INDIA","date":"May 26, 2023","format":false,"excerpt":"SUN PHARMACEUTICAL INDUSTRIES LIMITED (NSE : SUNPHARMA) Q4 FY23 Earnings Concall dated May. 26, 2023. Corporate Participants: Abhishek Sharma -- Head of Investor Relations Dilip Shanghvi -- Managing Director C. S. Muralidharan -- Chief Financial Officer Kirti Ganorkar -- Chief Executive Officer, India Business Abhay Gandhi -- Chief Executive Officer,\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":174494,"url":"https:\/\/alphastreet.com\/india\/sun-pharmaceutical-indus-sunpharma-q3-2025-earnings-call-transcript\/","url_meta":{"origin":131835,"position":5},"title":"SUN PHARMACEUTICAL INDUS (SUNPHARMA) Q3 2025 Earnings Call Transcript","author":"News desk","date":"January 22, 2026","format":false,"excerpt":"SUN PHARMACEUTICAL INDUS (NSE: SUNPHARMA) Q3 2025 Earnings Call dated Jan. 31, 2025 Corporate Participants: Abhishek Sharma \u2014 Vice President and Head of Investor Relations and Strategic Projects C.S. Muralidharan \u2014 Chief Financial Officer Kirti Ganorkar \u2014 Chief Executive Officer, India Business Abhay Gandhi \u2014 Chief Executive Officer, North America\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/131835","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=131835"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/131835\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=131835"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=131835"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=131835"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}